ICO annual conference May 15-17Webinar: Introducing OpRegen® from Lineage Cell Therapeutics
10 February 2021
Time: 6:30 PM
Duration: 90 minutes including question
Description: Lineage Cell Therapeutics Inc. (LCTX) is a biotechnology company developing three clinical-stage cell therapy programs based on allogeneic (“off-the-shelf”) cell lines and supported by one of the largest patent estates in cell therapy.
Their lead program is called OpRegen®.
OpRegen is a transplant of retinal pigment epithelium cells which are derived from pluripotent cell lines.
OpRegen is in Phase 1/2a clinical development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world.
All 24 patients have been enrolled in the clinical trial and data collection is ongoing.
Recent results included evidence of improved visual acuity, slower growth of GA, and notably, the first known clinical report of retinal tissue regeneration which has persisted to 23 months in one patient.
Additional data updates are expected in Q1 & Q2 2021.
Our guest speaker for this session is Brian Culley, who joined Lineage as CEO in September 2018. Mr. Culley is an experienced public biopharmaceutical company CEO, having served in that capacity at multiple publicly traded biotechnology companies. His broad experience includes the clinical development of pharmaceutical products from research through Phase 3, corporate partnering, institutional capital raising, and numerous other activities. His earlier positions include leadership roles in business development and technology transfer and as an early discovery researcher for Neurocrine Biosciences. He received a B.S. in biology from Boston College, a Masters in biochemistry and molecular biology from the University of California Santa Barbara, and an M.B.A. from The Johnson School at Cornell University.
Please register here to attend
For further information please contact stuart.lawler@